BioClarity AI

About BioClarity AI

BioClarity AI operates in the Software & AI space and is among the firms Bracken expects to track at SNMMI 2026.

Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.

What we're seeing

• FierceBiotech · 2026-11-14
  Bioclarity Ai appoints new Chief Medical Officer ahead of pivotal trial
  The announcement comes amid tightening Mo-99 and Lu-177 supply.
• BioPharma Reporter · 2026-08-21
  Bioclarity Ai signs supply agreement to support late-stage trials
  Industry observers expect more activity of this kind in the run-up to SNMMI 2026.
• Reuters Health · 2026-01-12
  Bioclarity Ai expands cyclotron capacity to meet Lu-177 demand
  Coverage notes the company's growing footprint in the radioligand therapy space.

Mocked while we wire the Exa integration. Headlines are illustrative.

What we expect to see at the booth

Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.